---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-009506"
form_type: "8-K"
ticker: "RCKT"
cik: "0001281895"
company_name: "ROCKET PHARMACEUTICALS, INC."
filed_at: "2024-02-26T23:59:59+00:00"
generated_at: "2026-06-05T14:39:32.057901+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Rocket Pharma Reports Q4 2023 Net Loss of $59.7M; PDUFA Date for KRESLADI Set for June 30, 2024

## Summary
- Cash, cash equivalents and investments stood at $407.5M as of Dec 31, 2023, providing runway into 2026.
- Net loss for Q4 2023 was $59.7M ($0.64 per share); full year 2023 net loss $245.6M ($2.92 per share).
- FDA extended Priority Review of KRESLADI BLA for severe LAD-I to June 30, 2024; no advisory committee needed.
- Fanconi Anemia BLA and MAA filings remain on track for H1 2024; pipeline milestones for 2024 reaffirmed.
- Appointed R. Keith Woods to Board; he previously led commercialization of Vyvgart at argenx.

## SEC filing metadata
- accession: 0001140361-24-009506
- form_type: 8-K
- ticker: RCKT
- cik: 0001281895
- company_name: ROCKET PHARMACEUTICALS, INC.
- filed_at: 2024-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1281895/000114036124009506/0001140361-24-009506-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1281895/000114036124009506/ef20022436_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-009506
- JSON: https://secwatch.observer/filing/0001140361-24-009506.json
- Plain text: https://secwatch.observer/filing/0001140361-24-009506.txt

## Key facts
- Earnings Releases
  ROCKET PHARMACEUTICALS, INC. reported the fourth quarter and year ended December 31, 2023 results: net income Net loss was $59.7 million and $245.6 million or $0.64 and $2.92 per share (basic and diluted) for the three and twelve, EPS $0.64 and $2.92 per share (basic and diluted) for the three and twelve months ended December 31, 2023.
  - Period: the fourth quarter and year ended December 31, 2023
  - Net income: Net loss was $59.7 million and $245.6 million or $0.64 and $2.92 per share (basic and diluted) for the three and twelve
  - EPS: $0.64 and $2.92 per share (basic and diluted) for the three and twelve months ended December 31, 2023
  - Result: reported results
  source text: Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
  evidence_url: https://www.sec.gov/Archives/edgar/data/1281895/000114036124009506/0001140361-24-009506-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.